Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well under-stood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. We recently published a paper entitled “Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma” in theJournal of the National Cancer Institute, providing a potential explanation for this limited beneift. We found that in mice bearing HCCs that had acquired resistance to sorafenib, tumors had switched from using angiogenesis for growth to co-opting the liver vas-culature by becoming more invasive. Accumulating evidence suggests that many human tumor types may use vessel co-option, which has profound implications for the use of anti-angiogenic agents for cancer treatment.
|作 者||Elizabeth A.Kuczynski(Sunnybrook Research Institute, 2075 Bayview Avenue, S-Wing, Room S217, Toronto, 0N M4N 3M5, Canada)；Robert S.Kerbel(Sunnybrook Research Institute, 2075 Bayview Avenue, S-Wing, Room S217, Toronto, 0N M4N 3M5, Canada)；|
|刊 名||癌症（英文版） 2016年35卷12期 641-644页|
|关键词||Vessel co-option Non-angiogenic Resistance Sorafenib Hepatocellular carcinoma|